Clinical Trial Update: Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura [Phase 3]

View source ↗

Summary

Phase 3 trial comparing romiplostim to standard of care in immune (idiopathic) thrombocytopenic purpura (ITP) has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Thrombocytopenia

Drugs mentioned

• Romiplostim (romiplostim)
• Standard of Care

Snippet

Sponsor: Amgen | Conditions: Idiopathic Thrombocytopenic Purpura, Thrombocytopenia | Phase 3 | Status: COMPLETED | Results posted: 2013-07-08